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Abstract
Resistance to 5-fluorouracil (5-FU) represents a major contributor to cancer-related mortality in
advanced colorectal cancer patients. Genetic variations and expression alterations in genes
involved in 5-FU metabolism and effect have been shown to modulate 5-FU sensitivity in vitro,
however these alterations do not fully explain clinical resistance to 5-FU-based chemotherapy. To
determine if alterations of DNA copy number in genes involved in 5-FU metabolism impacted
clinical resistance to 5-FU-based chemotherapy, we assessed thymidylate synthetase (TYMS) and
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thymidine phosphorylase (TYMP) copy number in colorectal liver metastases. DNA copy number
of TYMS and TYMP was evaluated using real time quantitative PCR in frozen colorectal liver
metastases procured from 62 patients who were pretreated with 5-FU-based chemotherapy prior to
surgical resection (5-FU exposed) and from 51 patients who received no pretreatment
(unexposed). Gain of TYMS DNA copy number was observed in 18% of the 5-FU exposed
metastases, while only 4% of the unexposed metastases exhibited TYMS copy gain (p=0.036). No
significant differences were noted in TYMP copy number alterations between 5-FU exposed and
unexposed metastases. Median survival time was similar in 5-FU exposed patients with metastases
containing TYMS amplification and those with no amplification. However, TYMS amplification
was associated with shorter median survival in patients receiving post-resection chemotherapy
(hazard ratio = 2.7, 95% confidence interval = 1.1 to 6.6; p=0.027). These results suggest
amplification of TYMS amplification as a putative mechanism for clinical resistance to 5-FU-based
chemotherapy and may have important ramifications for the post-resection chemotherapy choices
for metastatic colorectal cancer.
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Introduction
5-Fluorouracil (5-FU) is the backbone of treatment for advanced colorectal cancer, as nearly
all patients will receive a 5-FU-containing regimen 1, 2. 5-FU's prominence in advanced
colorectal cancer treatment is largely a function of its consistent efficacy throughout its five
decades of use 3. However, one of the biggest challenges for the management of advanced
colorectal cancer is 5-FU treatment failure, both inherent and acquired. Indeed, the five-year
survival of those with metastatic colorectal cancer is less than ten percent 4. Deaths due to
clinically-resistant metastatic colorectal cancer disproportionately account for why
colorectal cancer is presently the second leading cause of cancer-related mortality 5.
Numerous investigations into 5-FU resistance in metastatic colorectal cancer have focused
on genes within its known pharmacokinetic and pharmacodynamic pathways. One major
focus has been the enzyme, thymidylate synthetase (TYMS), a key therapeutic target of 5-
FU. Colorectal cancers that do not respond to 5-FU-based chemotherapy have been shown
to possess greater TYMS enzymatic activity than cancers that do respond 6. Likewise, high
levels of TYMS mRNA or protein in liver metastases have also been associated with lack of
clinical response to 5-FU in vivo 7-10. A recent meta-analysis of 24 studies has indicated that
metastatic colorectal tumours with low expression of TYMS are more sensitive to
fluoropyrimidine-based chemotherapy 11.
Similar expression studies have also been performed for thymidine phosphorylase (TYMP)
because of its role in 5-FU bioactivation. Overexpression of TYMP has been linked to
increased 5-FU sensitivity in vitro 12. Xenografts transfected to overexpress TYMP showed
a 43% decrease in size following 5-FU administration, whereas no response to 5-FU was
observed in the xenografts lacking TYMP-transfection 13. In one small study, an increase in
TYMP expression was observed in colorectal cancer metastases, which were significantly
more resistant to 5-FU than their matched primary tumours 14. More recently, low TYMP
expression was observed to be predictive of response to 5-FU based chemotherapy in
metastatic colorectal cancer patients 15. Conversely, increased expression of TYMP
measured by immunohistochemistry was associated with prolonged survival in metastatic
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colorectal cancer patients treated with capecitabine plus irinotecan 16. Thus the role TYMP
plays in resistance to chemotherapy remains to be clarified.
The underlying mechanism(s) for altered expression of genes and proteins important for
drug resistance has implications for the development of strategies to overcome clinical
resistance. For example, variants in the promoter region of genes are one mechanism
through which expression can be influenced. A polymorphic tandem repeat sequence in the
TYMS gene promoter region is associated with higher TYMS expression in tumours 17.
Additionally, one study of TYMS expression in colorectal cancer patients with liver-
confined metastases demonstrated an inverse association between high expressing TYMS
genotypes and tumour response to 5-FU-based chemotherapy 18. It also appears that
administration of 5-FU has the potential to increase TYMS expression, suggesting a
potential mechanism of acquired resistance to chemotherapy 19. Alterations in DNA copy
number are yet another potential mechanism for influencing gene expression. Amplification
of chromosome 18p11.32, the location of the TYMS gene, has been associated with
resistance to fluoropyrimidines in mouse colorectal cancer xenografts 20. TYMS gene copy
number has also been associated with clinical resistance to 5-FU. In a human study, TYMS
copy number gains occurred significantly more frequently in liver metastases from patients
who had received 5-FU than in metastases from patients who were 5-FU naïve 21, and these
copy number gains were associated with a 3.5-fold higher relative risk of death compared
with normal TYMS copy number 21. Importantly, the results of this small study have not
been replicated.
To gain insight into the mechanisms of clinical 5-FU resistance, we examined TYMS and
TYMP copy number in resected colorectal metastases from patients exposed and not exposed
to 5-FU-based chemotherapy. Gain of TYMS gene copy was associated with prior 5-FU
exposure suggesting this genetic alteration as a potential mechanism of resistance to 5-FU-
based chemotherapy.
Materials and Methods
Normal tissue and liver metastases were obtained from colorectal cancer patients undergoing
liver resection under a University of North Carolina Institution Review Board (UNC IRB)-
approved tissue banking protocol. Clinical information was retrospectively retrieved from
patient records and dates of death from the medical records or the Social Security Death
Index. Tissue specimen analysis and patient chart reviews was approved by the UNC IRB
(IRB number 07-1525) and was performed in accordance with Health Insurance Portability
and Accountability Act (HIPAA) regulations and the Helsinki Declaration. Patient samples
were categorized as “5-FU exposed” if the patients received 5-FU within the 6-months
preceding their liver resections; all other samples were classified as unexposed.
DNA was extracted from frozen liver metastases specimens using the Qiagen All Prep kit
(Qiagen Inc, Valencia, CA, USA) according to the manufacturer's protocol. Briefly, liver
metastases were lysed and homogenized via Tissuelyser (Qiagen). DNA quality was
assessed based on the optical density 260/280 ratio. DNA extractions were performed at
UNC Lineberger Comprehensive Cancer Center's Tissue Procurement Facility.
DNA copy number was determined by real time quantitative polymerase chain reaction
(qPCR) using an Applied Biosystems 7300 Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA). For TYMS copy number determination, the 20 μL qPCR reaction
was composed of 10 μL of TaqMan® universal PCR master mix (Applied Biosystems), 10
μL of primer probe mix containing primers and probes for FAM™-labelled TYMS (final
concentration of primers = 600 nM, probe = 200 nM) and VIC™-labelled RNaseP
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(catalogue #: 4316844; final concentration at 1×) and 20 ng of DNA (dried in wells of the
PCR plate overnight before adding the reaction mixture). These qPCR assays were
performed in triplicate according to the following program: 50°C for 2 minutes, 95°C for 10
minutes, 40 cycles at 95°C for 20 seconds, and 60°C for 1 minute. The primer and probe
mix for TYMS contained a forward primer – GCCTCGGTGTGCCTTTCA, reverse primer –
CGTGATGTGCGCAATCATG and the TaqMan® probe –
CATCGCCAGCTACGCCCTGCTC 22. The colorectal cancer cell line, H630R10 (kindly
provided by Prof Patrick Johnston, Queen's University, Belfast), was used as a positive
control in determination of TYMS copy number as it exhibits TYMS copy number gain 23.
For TYMP copy number determination, the 20 μL qPCR reaction was composed of 10 μL of
SYBR® Green universal PCR master mix (Applied Biosystems), 10 μL of PCR primers for
TYMP and RNaseP (final concentration = 4 μM), and 20 ng of DNA (dried in wells of the
PCR plate overnight before adding the reaction mixture). These qPCR assays were
performed in duplicate, with the assays for TYMP and RNaseP for a single sample always
run on the same plate according to the following program: 50°C for 2 minutes, 95°C for 10
minutes, 40 cycles at 95°C for 15 seconds, 56°C for 30 seconds and 70°C for 30 seconds.
The primers for TYMP were: forward primer – GTTCTCCATTGTCTCCAACCTC and
reverse primer – AACTTAACGTCCACCACCAGAG 22. The SYBR® green primers for
RNaseP were: forward primer - TGGGAAGGTCTGAGACTAGGG and reverse primer -
CGTTCTCTGGGAACTCACCT. All primers were designed using the Primer3 program 24.
The analysis of DNA copy number for each sample was performed using the comparative Ct
(2-ΔΔCt) method as described previously 22, in which the threshold cycle (Ct) numbers were
generated using the 7300 System SDS Software, version 1.4 (Applied Biosystems). DNA
copy numbers were normalized for TYMS and TYMP to the control gene, RNaseP, because
normal liver has two copies of this gene.
The range of values for normal TYMS and TYMP were determined by performing the assays
on genomic DNA isolated from cell lines from the Centre d'Etude du Polymorphisme
Humain (CEPH) collection, which are EBV-transformed lymphoblastoid cells taken from
healthy individuals believed to have normal TYMS and TYMP copy number. Cell lines were
obtained from Coriell (Coriell Institute for Medical Research, Camden, NJ, USA).
Metastases samples with copy number values more than 2 standard deviations greater than
the mean CEPH copy number (2.53 for TYMS, 2.54 for TYMP) were considered to have
copy number gains and those with values more than 2 standard deviations less than the mean
CEPH copy number (1.31 for TYMS, 1.52 for TYMP) were considered to have copy number
losses.
The differences in proportions of demographic characteristics and number of patients with
copy number alterations in the 5-FU exposed and unexposed patients were compared using
Fisher's exact test; Wilcoxon Rank Sum tests were used to compare continuous variables
between the two groups. Based on the available sample size we had 80% power to detect a
0.15 difference between 5-FU exposed and unexposed groups. Kaplan-Meier analysis was
performed to test the effect of genetic alterations on overall survival and significance was
assessed using log rank tests. Overall survival data was calculated from the date of surgery
to the date of death or last follow-up and Cox regression was used to calculate hazard ratios.
All statistical tests were 2-sided and the significance level was set at p<0.05.
Results
Demographics
The study population consisted of 113 metastatic colorectal cancer patients who had their
liver metastases surgically resected (62 exposed and 51 unexposed to 5-FU prior to surgical
resection). Patient characteristics are listed in Table 1. The mean age at diagnosis in the
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unexposed group was 6 years greater than in the 5-FU exposed group (p=0.01); no other
statistically significant differences in demographic data were observed between the two
groups.
TYMS
TYMS DNA copy number was obtainable from 111 samples (62 5-FU exposed and 49
unexposed). The values of TYMS copy number ranged from 1.06 to 3.80 for the 5-FU
exposed samples and 1.12 to 3.28 for the unexposed samples. The median copy number was
1.89 for exposed samples and 1.74 for unexposed samples. 5-FU exposed samples exhibited
a significantly greater frequency of TYMS amplification compared to unexposed samples
(19% vs. 4%, p=0.036; Figure 1). TYMS loss was infrequent in both 5-FU exposed and
unexposed groups (3 samples for each group).
TYMP
TYMP DNA copy number was obtainable for 99 samples (54 5-FU exposed and 45
unexposed). The values of TYMP copy number ranged from 0.93 to 6.78 for the 5-FU
exposed samples and 1.06 to 6.98 for the unexposed samples. The median copy number was
1.97 for 5-FU exposed samples and 2.00 for unexposed samples. While a greater percentage
of tumours exhibited TYMP copy number alterations than TYMS copy number alterations,
the prevalence of TYMP copy number alterations was similar in the two treatment groups
(37% for 5-FU exposed and 42% for unexposed metastases; p=0.68). Amplification of
TYMP was roughly equivalent in both treatment groups (20% for 5-FU exposed and 29% for
unexposed; p=0.35), as was loss of TYMP (17% for 5-FU exposed and 13% for unexposed;
p=0.78; Figure 2).
As one of our hypotheses was that TYMS amplification would result in poorer response to 5-
FU we compared overall survival in patients with TYMS gains (n=11) to patients with
normal or low TYMS copy (n=50). No difference in survival was demonstrated between
patients with normal/low TYMS copy number and those with TYMS gain (Figure 3A: Median
survival for normal/low copy = 2.52 years, TYMS gain = 2.11 years, p=0.13). However, for
the subset of patients treated with chemotherapy after surgical resection of their metastases
for which we have TYMS copy number data (n=54), TYMS gain (n=8) was associated with a
poorer median survival post-resection compared to patients with normal or low TYMS copy
number (n=46) (Figure 3B: 2.11 years vs. 3.61 years, p=0.027). This difference represented
a 2.7-fold higher hazard of death compared to patients without TYMS copy number gain
(95% CI = 1.1 to 6.6). There were no associations between TYMP copy number alterations
and survival for either the whole patient population or the treated and untreated subgroups
(data not shown).
Discussion
Aneuploidy is a common phenomenon in cancer which can have a pharmacologic impact if
the altered chromosomal regions contain genes important for modulating drug response.
Trisomies are common in acute lymphoblastic leukaemia cells 25 and chromosomal gains
that encompass the pharmacologically important genes thiopurine S-methyltransferase and
gamma-glutamyl hydrolase have been associated with higher activity of the encoded
proteins in leukemic cells, which would be expected to impact the clinical response to
mercaptopurine 26. In breast cancer, amplification of v-erb-b2 erythroblastic leukaemia viral
oncogene homolog 2 (ERBB2 - also known as HER-2/neu) is found in a subset of tumours,
which has prognostic importance 27 and is associated with decreased response to tamoxifen
28. In non-small-cell lung cancer, amplification of epidermal growth factor receptor (EGFR)
is associated with better response to the EGFR tyrosine kinase inhibitor, gefitinib 29. Thus
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one mechanism for drug resistance appears to include copy number alterations of
pharmacologically important genes in cancer tissue which can impact drug response 26.
Previously, copy number gains of the gene TYMS were shown to be inversely correlated
with survival in a small study of patients with colorectal metastases following exposure to 5-
FU 21. Our analysis of gene copy number in a larger population indicates a significant
association between exposure to 5-FU-based chemotherapy and amplification of the TYMS
gene in surgically resected metastatic colorectal lesions, consistent with the aforementioned
results. While Wang and colleagues noted TYMS gains in only tumours exposed to 5-FU 21,
our results suggest that amplification of TYMS in metastatic colorectal cancer can be found
in the absence of 5-FU exposure, although it is possible patients received a 5-FU-based
chemotherapy regimen for their primary disease before the onset of metastasis. It is
unknown whether exposure to 5-FU induces amplification of the chromosomal region
containing the TYMS gene or if 5-FU chemotherapy preferentially targets cancer cells
without the amplification, resulting in the survival of resistant cells with TYMS
amplification. However, it has been shown that expression of TYMS increases after bolus
exposure to 5-FU in vivo 19. Additional work needs to be conducted to determine the
mechanism for the observed amplification of TYMS in colorectal liver metastases following
exposure to 5-FU.
The importance of TYMS amplification for metastatic colorectal cancer patients was
illustrated by previous results that indicated TYMS amplification resulted in shorter survival
times in patients pretreated with 5-FU 21. Our results do not strongly support this hypothesis,
although our patients with tumours exhibiting TYMS amplification exhibited a trend toward
shorter (almost 5 months) survival that did not reach statistical significance (Figure 3A).
However, it should be noted that the patient cohort examined in the study by Wang and
colleagues were treated only with 5-FU, as this was the standard of care therapy at the time
of that study 21, whereas the patients examined in this study were treated with neoadjuvant
chemotherapy regimens containing 5-FU plus oxaliplatin, irinotecan and/or bevacizumab.
Since TYMS amplification is not significantly associated with shorter survival time in
patients pre-treated with 5-FU-based chemotherapy, this suggests that the use of additional
chemotherapeutic agents in the neoadjuvant setting lessens the impact of TYMS
amplification on clinical resistance. On the other hand, there may be some bias in our patient
groups, in terms of both age and comorbidity, which favour some patients to receive pre-
operative chemotherapy, which has the potential to mask any associations with survival.
However, in those patients treated with adjuvant chemotherapy following surgical resection
of their metastases, median survival time was 1 ½ years shorter in patients with tumours
containing TYMS amplification than those with normal or lower TYMS copy number (Figure
3B). This suggests that tumours exhibiting TYMS amplification respond more poorly to
chemotherapy. Alternatively, TYMS amplification could be associated with more aggressive
tumour behaviour. Since the number of patients with tumours exhibiting TYMS
amplification is small, additional studies need to be conducted to confirm the importance of
TYMS amplification in metastatic colorectal cancer. If validated, TYMS copy number
alteration could potentially serve as a biomarker for clinical resistance to 5-FU based
adjuvant chemotherapy in metastatic colorectal cancer patients, at which point, TYMS copy
number gain in resected tumours could be used to indicate which patients should receive an
adjuvant chemotherapy regimen devoid of 5-FU due to resistance.
The cause of 5-FU resistance in metastatic colorectal cancer patients is believed to be
multifactorial 6, 30-33. TYMS amplification clearly does not fully explain resistance to 5-FU
based chemotherapy, as some patients without gain of TYMS also had short survival times.
A pathway-based approach to interrogate all the genes and proteins that are postulated to be
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involved in 5-FU metabolism and efficacy is a more likely strategy to identify the relevant
mechanisms underlying clinical resistance to 5-FU. While our data do not support a role for
TYMP copy number alterations in resistance to 5-FU based chemotherapy, there are still
many other genes that could logically be investigated. In addition, the problem of clinical
resistance has become more complicated by the additional chemotherapeutic agents that are
utilized with 5-FU in metastatic colorectal cancer patients. Detailed investigation of the role
played by genes relevant to each of the chemotherapy agents used will provide a more
complete picture of the mechanism(s) underlying clinical resistance to complex drug
regimens. In addition, since our knowledge of the mechanisms through which these drugs
exert their anticancer effects is incomplete, an unbiased approach, such as through genome-
wide profiling, may be required to fully elucidate the mechanisms underlying clinical
resistance in metastatic colorectal cancer patients.
In conclusion, we found neoadjuvant treatment with 5-FU-based chemotherapy was
associated with gain of TYMS gene copy number. In addition, among patients treated with
chemotherapy following surgical resection of their metastases, those with tumours
containing TYMS amplification exhibited significantly shorter overall survival time. These
data, along with previously published results, suggest that TYMS amplification may be
involved in clinical resistance to 5-FU-based chemotherapy in metastatic colorectal cancer
patients. If validated in larger clinical trials, these results suggest a prognostic importance
for TYMS copy number gain in metastatic colorectal cancer patients, which can assist in the
selection of the chemotherapy regimens most likely to be of clinical benefit.
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Histogram of TYMS copy number in tumours from 5-FU exposed and unexposed patients.
Tumours with copy number < 1.31 were classified as loss of copy number and tumours with
copy number > 2.53 were classified as gain of copy number. The p-values correspond to the
Fisher's Exact Test comparing each group to the other two combined.
Watson et al. Page 10














Histogram of TYMP copy number in tumours from 5-FU exposed and unexposed patients.
Tumours with copy number < 1.52 were classified as loss of copy number and tumours with
copy number > 2.54 were classified as gain of copy number. The p-values correspond to the
Fisher's Exact Test comparing each group to the other two combined.
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Effect of TYMS amplification on overall survival in metastatic colorectal cancer patients
receiving chemotherapy. 3A: Kaplan-Meier analysis of overall survival in patients with
metastatic colorectal cancer receiving neoadjuvant chemotherapy prior to surgical resection
of their metastases (median survival time for TYMS amplification = 2.11 years, median
survival for normal/low copy = 2.52 years). 3B: Kaplan-Meier analysis of overall survival in
patients with metastatic colorectal cancer receiving adjuvant chemotherapy following
surgical resection of their metastases (median survival time for TYMS amplification = 2.11
years, median survival for normal/low copy = 3.61 years).
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Table 1
Clinical cohort demographics
Characteristic Unexposed 5-FU Exposed P-value
Gender
 Male 31 (61%) 27 (44%)
0.089
 Female 20 (39%) 35 (56%)
Race
 White 36 (71%) 48 (77%)
0.46 Black 12 (23%) 13 (21%)
 Asian/Other 3 (6%) 1 (2%)
Age (mean) at diagnosisa 65 (range 42 – 86) 59 (range 38-85) 0.01
TNM staging system: Tb
 0 12 10
0.15
 1 5 2
 2 7 5
 3 22 38
 4 3 1
TNM staging system: Nb
 0 27 25
0.47 1 14 17
 2 8 14
TNM staging system: Mb
 0 30 28
0.12
 1 17 31
Initial Number of Liver Metastases
 Unknown 7 13
0.24
 1 27 23
 2 11 12
 >2 6 14
 Range 1-6 1-14
 Median 1 1
Post-resection chemotherapy
 Yes 22 34
0.41 No 27 25
 Unknown 2 3
Length of Neoadjuvant Chemotherapy (pretreatment in days)
 Mean 140
NAc Median 110
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Characteristic Unexposed 5-FU Exposed P-value
 Range 27-564
a
Diagnosis refers to diagnosis of liver metastasis
b
TNM staging system from the AJCC Cancer Staging Handbook (2002).
c
NA = not applicable
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